DUBLIN–(BUSINESS WIRE)–The “Schizoaffective Disorder – Pipeline Insight, 2023” clinical trials has been added to ResearchAndMarkets.com’s offering.
The “Schizoaffective Disorder – Pipeline Insight, 2023” report offers comprehensive insights into the Schizoaffective disorder pipeline landscape, encompassing information on more than 4 companies and over 4 pipeline drugs. It provides detailed profiles of these pipeline drugs, including their clinical and nonclinical stages of development. The report also evaluates these therapeutics based on product type, development stage, route of administration, and molecule type, while also highlighting any inactive pipeline products in this field.
The report delivers a thorough understanding of the current scenario and growth prospects within the Schizoaffective disorder indication. It furnishes an extensive overview of the Schizoaffective disorder pipeline landscape, including information on the disease itself and treatment guidelines.
The assessment section of the report includes a comprehensive commercial assessment of Schizoaffective disorder, as well as a clinical evaluation of the pipeline products currently in development. It offers detailed descriptions of these drugs, covering their mechanisms of action, clinical studies, potential NDA approvals, and various product development activities such as technology used, collaborations, licensing agreements, mergers and acquisitions, funding, designations, and other pertinent product-related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Schizoaffective disorder R&D. The therapies under development are focused on novel approaches to treat/improve Schizoaffective disorder.
Schizoaffective disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Schizoaffective disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Schizoaffective disorder drugs.
Schizoaffective disorder Emerging Drugs Chapters
This segment of the Schizoaffective disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Schizoaffective Disorder Emerging Drugs
Risperidone: Lyndra Therapeutics
Risperidone (LYN-005) is an oral, extended release formulation, presented in a capsule dosage form with an aim of reducing the frequency of dosing orally-administered medications to once weekly or less. It is a dopamine D2 receptor antagonists and is currently under Phase II development for the treatment of schizoaffective disorder.
Lyndra Therapeutics announced the positive outcome of an end-of-phase II meeting with the US Food and Drug Administration (FDA) suggesting a clear path to approval for its weekly risperidone for the treatment of schizophrenia and schizoaffective disorder, LYN-005. The company plans to initiate its pivotal program for LYN-005 in early 2022.
Schizoaffective disorder: Therapeutic Assessment
This segment of the report provides insights about the different Schizoaffective disorder drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Schizoaffective disorder
There are approx. 4+ key companies which are developing the therapies for Schizoaffective disorder. The companies which have their Schizoaffective disorder drug candidates in the most advanced stage, i.e. Phase III include, Lyndra Therapeutics.
Key Questions Answered
- How many companies are developing Schizoaffective disorder drugs?
- How many Schizoaffective disorder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Schizoaffective disorder?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Schizoaffective disorder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Schizoaffective disorder and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Lyndra Therapeutics
- Luye Pharma Group Ltd.
- BioXcel Therapeutics Inc
- Reviva Pharma
Key Products
- Risperidone
- LY03010
- BXCL501
- RP5063
Phases
The report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Schizoaffective disorder Report Insights
- Schizoaffective disorder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Schizoaffective disorder Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/5sabb0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
